Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo

Oncotarget

Volumn 6, Issue 7, 2015, Pages 4976-4991

  Huang, Han Li ^a   Peng, Chieh Yu ^b,c   Lai, Mei Jung ^d   Chen, Chun Han ^a   Lee, Hsueh Yun ^d   Wang, Jing Chi ^d   Liou, Jing Ping ^d   Pan, Shiow Lin ^d   Teng, Che Ming ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Akt; Apoptosis; B cell lymphoma; Histone deacetylase (HDAC); MPT0E028

Indexed keywords

3 (1 BENZENESULFONYL 2,3 DIHYDRO 1H INDOL 5 YL) N HYDROXYACRYLAMIDE; HISTONE DEACETYLASE INHIBITOR; ONCOPROTEIN; PROTEIN KINASE B; STAT PROTEIN; UNCLASSIFIED DRUG; VORINOSTAT; 3-(1-BENZENESULFONYL-2,3-DIHYDRO-1H-INDOL-5-YL)-N-HYDROXYACRYLAMIDE; HYDROXAMIC ACID; INDOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B CELL LYMPHOMA CELL; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG STRUCTURE; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; ONCOGENE MYC; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STAT GENE; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; ANIMAL; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; LYMPHOMA, B-CELL; NONOBESE DIABETIC MOUSE; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PATHOLOGY; RANDOMIZATION; SCID MOUSE; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; LYMPHOMA, B-CELL; MALE; MICE; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; RANDOM ALLOCATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924964704     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3213     Document Type: Article

References (47)

1. Siegel R, Ward E, Brawley O and Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: a cancer journal for clinicians. 2011; 61(4):212-236.
2. Mahadevan D and Fisher RI. Novel therapeutics for aggressive non-Hodgkin's lymphoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29(14):1876-1884.
3. Xu WS, Parmigiani RB and Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007; 26(37):5541-5552.
4. Marks PA and Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy. Journal of cellular biochemistry. 2009; 107(4):600-608.
5. Stimson L, Wood V, Khan O, Fotheringham S and La Thangue NB. HDAC inhibitor-based therapies and haematological malignancy. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2009; 20(8):1293-1302.
6. Mann BS, Johnson JR, Cohen MH, Justice R and Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. The oncologist. 2007; 12(10):1247-1252.
7. Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W and Kim YH. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28(29):4485-4491.
8. Hennessy BT, Smith DL, Ram PT, Lu Y and Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature reviews Drug discovery. 2005; 4(12):988-1004.
9. Liu P, Cheng H, Roberts TM and Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nature reviews Drug discovery. 2009; 8(8):627-644.
10. Manning BD and Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007; 129(7):1261-1274.
11. Pal SK, Reckamp K, Yu H and Figlin RA. Akt inhibitors in clinical development for the treatment of cancer. Expert Opinion on Investigational Drugs. 2010; 19(11):1355-1366.
12. Huang H-L, Lee H-Y, Tsai A-C, Peng C-Y, Lai M-J, Wang J-C, Pan S-L, Teng C-M and Liou J-P. Anticancer Activity of MPT0E028, a Novel Potent Histone Deacetylase Inhibitor, in Human Colorectal Cancer HCT116 Cells In Vitro and In Vivo. PloS one. 2012; 7(8):e43645.
13. Chen MC, Chen CH, Wang JC, Tsai AC, Liou JP, Pan SL and Teng CM. The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells. Cell death & disease. 2013; 4:e810.
14. Chen CH, Chen MC, Wang JC, Tsai AC, Chen CS, Liou JP, Pan SL and Teng CM. Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014; 20(5):1274-1287.
15. Richon VM, Sandhoff TW, Rifkind RA and Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97(18):10014-10019.
16. Chen J, Ghazawi FM, Bakkar W and Li Q. Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B. Molecular cancer. 2006; 5:71.
17. Chen CS, Weng SC, Tseng PH and Lin HP. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. The Journal of biological chemistry. 2005; 280(46):38879-38887.
18. Mehrotra P, Riley JP, Patel R, Li F, Voss L and Goenka S. PARP-14 functions as a transcriptional switch for Stat6-dependent gene activation. The Journal of biological chemistry. 2011; 286(3):1767-1776.
19. Juan LJ, Shia WJ, Chen MH, Yang WM, Seto E, Lin YS and Wu CW. Histone deacetylases specifically down-regulate p53-dependent gene activation. The Journal of biological chemistry. 2000; 275(27):20436-20443.
20. Zhang X, Chen X, Lin J, Lwin T, Wright G, Moscinski L, Dalton W, Seto E, Wright K, Sotomayor E and Tao J. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene. 14 June 2012; 31:3002-3008.
21. Shelley L B. Histone modifications in transcriptional regulation. Current Opinion in Genetics & Development. 2002; 12(2):142-148.
22. Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F, Darzynkiewicz Z, Fojo T and Bates SE. Histone Deacetylase Inhibitors All Induce p21 but Differentially Cause Tubulin Acetylation, Mitotic Arrest, and Cytotoxicity. Molecular cancer therapeutics. 2002; 1(11):937-941.
23. Glozak MA, Sengupta N, Zhang X and Seto E. Acetylation and deacetylation of non-histone proteins. Gene. 2005; 363:15-23.
24. Mercurio C, Minucci S and Pelicci PG. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacological research: the official journal of the Italian Pharmacological Society. 2010; 62(1):18-34.
25. LoPiccolo J, Blumenthal GM, Bernstein WB and Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy. 2008; 11(1-2):32-50.
26. Denlinger CE, Rundall BK and Jones DR. Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo. The Journal of thoracic and cardiovascular surgery. 2005; 130(5):1422-1429.
27. Ellis L, Ku S, Ramakrishnan S, Lasorsa E, Azabdaftari G, Godoy A and Pili R. Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer. Oncotarget. 2013; 4(12):2225-2236.
28. Rahmani M, Reese E, Dai Y, Bauer C, Payne SG, Dent P, Spiegel S and Grant S. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer research. 2005; 65(6):2422-2432.
29. Nishioka C, Ikezoe T, Yang J, Koeffler HP and Yokoyama A. Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2008; 22(12):2159-2168.
30. Verheul HM, Salumbides B, Van Erp K, Hammers H, Qian DZ, Sanni T, Atadja P and Pili R. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14(11):3589-3597.
31. Wedel S, Hudak L, Seibel JM, Makarevic J, Juengel E, Tsaur I, Wiesner C, Haferkamp A and Blaheta RA. Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells. Clinical & experimental metastasis. 2011; 28(5):479-491.
32. Bali P, George P, Cohen P, Tao J, Guo F, Sigua C, Vishvanath A, Scuto A, Annavarapu S, Fiskus W, Moscinski L, Atadja P and Bhalla K. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clinical cancer research: an official journal of the American Association for Cancer Research. 2004; 10(15):4991-4997.
33. Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, Wang H-G, Atadja P and Bhalla K. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Molecular cancer therapeutics. 2003; 2(10):971-984.
34. Sato S, Fujita N and Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97(20):10832-10837.
35. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E and Bhalla K. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. The Journal of biological chemistry. 2005; 280(29):26729-26734.
36. Sikandar S, Dizon D, Shen X, Li Z, Besterman J and Lipkin SM. The Class I Hdac Inhibitor Mgcd0103 Induces Cell Cycle Arrest and Apoptosis in Colon Cancer Initiating Cells by Upregulating Dickkopf-1 and Non-Canonical Wnt Signaling. Oncotarget. 2010; 1(7):596-605.
37. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, Holloway AJ and Johnstone RW. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(10):3697-3702.
38. Buglio D, Georgakis GV, Hanabuchi S, Arima K, Khaskhely NM, Liu YJ and Younes A. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood. 2008; 112(4):1424-1433.
39. Blagosklonny MV, Trostel S, Kayastha G, Demidenko ZN, Vassilev LT, Romanova LY, Bates S and Fojo T. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer research. 2005; 65(16):7386-7392.
40. Li D, Marchenko ND and Moll UM. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell death and differentiation. 2011; 18(12):1904-1913.
41. Taub R, Kirsch I, Morton C, Lenoir G, Tronick S, Aaronson S and Leder P. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human burkitt lymphoma and murine plasmacytoma cells. Proceedings of the National Academy of Sciences of the United States of America. 1982; 79:7837-7841.
42. Patel JH, Du Y, Ard PG, Phillips C, Carella B, Chen CJ, Rakowski C, Chatterjee C, Lieberman PM, Lane WS, Blobel GA and McMahon SB. The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60. Molecular and cellular biology. 2004; 24(24):10826-10834.
43. Gatti L, Sevko A, Cesare MD, Arrighetti N, Manenti G, Ciusani E, Verderio P, Ciniselli CM, Cominetti D, Carenini N, Corna E, Zaffaroni N, Rodolfo M, Rivoltini L, Umansky V and Perego P. Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals. Oncotarget. 2014; 5(12):4516-4528.
44. Gueugnon F, Cartron P-F, Charrier C, Bertrand P, Fonteneau J-F, Gregoire M and Blanquart C. New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells. Oncotarget. 2014; 5(12):4504-4515.
45. Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SGT, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S and Bhalla KN. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget. 2014; 5(14):5637-5650.
46. Shimizu R, Kikuchi J, Wada T, Ozawa K, Kano Y and Furukawa Y. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2010; 24(10):1760-1768.
47. Kroesen M, Gielen PR, Brok IC, Armandari I, Hoogerbrugge PM and Adema GJ. HDAC inhibitors and immunotherapy; a double edged sword? Oncotarget; Vol 5, No 16. 2014.